BERGEN, Norway, June 15, 2020 /PRNewswire/ -- BerGenBio ASA
(OSE:BGBIO), a clinical-stage biopharmaceutical company developing
novel, selective AXL kinase inhibitors for severe unmet medical
need, is pleased to announce that its abstract has been accepted
for oral virtual presentation at the 3rd Annual Next Gen
Immuno-Oncology Congress, which takes place from 25-26 June 2020.
The presentation to be given by Prof. Hani Gabra MD PhD, CMO
BerGenBio, will provide an update of results from a phase II trial
(BGBC008), evaluating bemcentinib in combination with MSD's
Keytruda® (pembrolizumab) in previously treated
non-small cell lung cancer (NSCLC) patients with confirmed
progression, including positive top line clinical and translational
data from stage 1 of Cohort B in patients having failed prior
immune checkpoint therapy.
The presentation will be available on the Company website in the
Presentations section on 25 June:
www.bergenbio.com/investors/presentations/
Title: Targeting AXL to leverage checkpoint
immunotherapy: Updated results of the BGBC008 phase II study
of bemcentinib and pembrolizumab in recurrent NSCLC
Date and time: 25 June 2020, 10am EST
Session name: Targeted Antibodies and Cellular
Therapy
About AXL
AXL kinase is a cell membrane receptor and an essential mediator
of the biological mechanisms underlying life-threatening diseases.
In cancer, AXL suppresses the body's immune response to tumours and
drives cancer treatment failure across many indications. AXL
expression defines a very poor prognosis subgroup in most cancers.
AXL inhibitors, therefore, have potential high value at the centre
of cancer combination therapy, addressing significant unmet medical
needs and multiple high-value market opportunities. Research has
also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially
first-in-class selective AXL inhibitor in a broad phase II clinical
development programme. Ongoing clinical trials are investigating
bemcentinib in multiple solid and haematological tumours, in
combination with current and emerging therapies (including
immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular
catalytic kinase domain of AXL receptor tyrosine kinase and
inhibits its activity. Increase in AXL function has been linked to
key mechanisms of drug resistance and immune escape by tumour
cells, leading to aggressive metastatic cancers.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer, leukaemia and COVID19. A
first-in-class functional blocking anti-AXL antibody, tilvestamab,
is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient
populations most likely to benefit from bemcentinib: this is
expected to facilitate more efficient registration trials
supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen,
Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo
Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
Contacts
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy
Featherstone, Carina
Jurs
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in Norway
Jan Petter Stiff, Crux
Advisers
stiff@crux.no
+47 995 13 891
This information was brought to you by Cision
http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/15728/3133172/1263274.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/bergenbio-to-present-top-line-translational-phase-ii-data-with-bemcentinib-in-combination-with-keytruda-in-nsclc-patients-at-next-gen-immuno-oncology-congress-301076599.html
SOURCE BerGenBio ASA